ClinicalTrials.gg
Active, not recruitingNCT04475926Updated Nov 6, 2025

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

An observational study in Limb-girdle Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Active, not recruiting at 26 sites in 10 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Sarepta Therapeutics, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
205
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
5th of 13
205 · median 101
Started
2021
with 1 other
Observational
13 of 30
3 open now
Registered
19th of 30
by date
Lead sponsor
8 of 30
Sarepta Therapeutics, Inc.

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 5th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2021, is one of 13 observational ones, and was the 19th registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1).

These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 5 years after enrollment for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a North Star Assessment for Dysferlinopathy (NSAD) ≥ 25 at Baseline, up to 3 years for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a NSAD \< 25 at Baseline, and up to 3 years for participants with LGMD2A/R1. Additional participant data will be collected from the time the individual began experiencing LGMD symptoms to the present.

Read the detailed description

LGMD Type 2A, 2C, and 2D cohorts are now closed. Enrollment in the LGMD Type 2E cohort is closed and participants will be followed for up to five years.

03

Conditions studied

  • Limb-girdle Muscular Dystrophy

Keywords

  • North Star Assessment for Dysferlinopathy (NSAD)
  • Performance of Upper Limb (PUL)
  • Pulmonary function tests (PFTs)
  • Ambulatory
  • Non-Ambulatory
  • Limb-girdle
  • LGMD
  • sarcoglycanopathy
  • β -sarcoglycan
  • Muscular Dystrophy
  • α -sarcoglycan
  • γ -sarcoglycan
  • LGMD-2D/R3
  • LGMD-2E/R4
  • LGMD-2C/R5
  • LGMD2A/R1
  • Clinical Outcomes Assessment
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population for this study is ambulatory or non-ambulatory participants ≥ 4 years of age with confirmed genetic diagnosis of LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, or LGMD2A/R1.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant ≥ 4 years of age who demonstrate symptoms of LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, or LGMD2A/R1 in the opinion of the investigator (eg, muscle weakness, loss of function, delayed milestones).
  • Confirmed clinical and genetic diagnosis of LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, or LGMD2A/R1.

Exclusion criteria

Exclusion Criteria:

  • Demonstrates cognitive delay or impairment that could confound motor development, in the opinion of the Investigator.
  • Has a medical condition, in the opinion of the Investigator, that might compromise participants ability to comply with study requirements.
  • Is participating in other interventional study(ies) at the time of enrollment in this study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
205 participants (actual)
Patient registry
No

Groups and cohorts

  • LGMD2E/R4 Cohort

    Participants with LGMD2E/R4 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.

  • LGMD2D/R3 Cohort

    Participants with LGMD2D/R3 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.

  • LGMD2C/R5 Cohort

    Participants with LGMD2C/R5 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.

  • LGMD2A/R1 Cohort

    Participants with LGMD2A/R1 will be enrolled in this cohort. Enrollment will be capped according to age as follows: 4 to 7 years age range, 8 to 16 years age range, and ≥17 years age range through the course of the study.

06

What researchers measure

Primary outcomes

  1. NSAD Total Score

    Time frame: Baseline up to Month 60

  2. Time to Rise from the Floor

    Time frame: Baseline up to Month 60

  3. Time of 10-Meter Walk/Run [10MWR]

    Time frame: Baseline up to Month 60

  4. Time to Ascend 4 Steps

    Time frame: Baseline up to Month 60

  5. Ankle Range of Motion (ROM)

    Time frame: Baseline up to Month 60

  6. Dimension of the Performance of the Upper Limb (PUL)

    Time frame: Baseline up to Month 60

  7. Timed Up and Go (TUG)

    Time frame: Baseline up to Month 60

  8. Time of 100-Meter Walk/Run (100MWR)

    Time frame: Baseline up to Month 60

  9. Pulmonary Function Test: Forced Vital Capacity (FVC)

    Time frame: Baseline up to Month 60

07

Study locations

26 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Sep 2030, 112 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
Jul 17, 2020
StartActual
Apr 22, 2021
Primary completionEst.
Sep 5, 2030
CompletionEst.
Sep 5, 2030
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04475926
Responsible party
Sponsor
First posted
Jul 17, 2020
Start date
Apr 22, 2021
Primary completion
Sep 5, 2030 (estimated)
Completion
Sep 5, 2030 (estimated)
Last update
Nov 6, 2025

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion